BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34414112)

  • 21. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
    Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 23. Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis.
    Spyropoulos E; Kotsiris D; Spyropoulos K; Panagopoulos A; Galanakis I; Mavrikos S
    Clin Genitourin Cancer; 2017 Feb; 15(1):129-138.e1. PubMed ID: 27460552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors of bone metastasis in patients with newly diagnosed prostate cancer.
    Chaoying L; Chao M; Xiangrui Y; Yingjian H; Gang Z; Yunhan R; Yu G
    Eur Rev Med Pharmacol Sci; 2022 Jan; 26(2):391-398. PubMed ID: 35113414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the performance of PI-RADS v2 in the non-academic setting.
    Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
    Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical research analysis based on prostate cancer screening diagnosis.
    Shan J; Geng X; Liu Z; Lu Y; Zhou R; Zhang Z; Xu H; Zhou X; Ma W; Zhu H; Shi H
    Andrologia; 2022 May; 54(4):e14371. PubMed ID: 35014705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new predictor is comparable to the updated nomogram in predicting the intermediate- and high-risk prostate cancer but outperforms nomogram in reducing the overtreatment for the low-risk Pca.
    Wang H; Tai S; Zhang L; Zhou J; Liang C
    Cancer Manag Res; 2019; 11():3753-3763. PubMed ID: 31118794
    [No Abstract]   [Full Text] [Related]  

  • 28. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
    Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
    Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
    Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
    [No Abstract]   [Full Text] [Related]  

  • 30. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
    PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy.
    Jeong IG; Lim JH; Hwang SS; Kim SC; You D; Hong JH; Ahn H; Kim CS
    Prostate Int; 2013; 1(2):69-75. PubMed ID: 24223405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of extraprostatic extension in patients with clinically organ-confined prostate cancer.
    Lin S; Zhang Q; Li P; Li Z; Sun Y; Shao Y; Zhang X; Fu S
    Urol Int; 2014; 92(3):282-8. PubMed ID: 24280781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging/transrectal ultrasound fusion-derived data.
    Ding Z; Wu H; Song D; Tian H; Ye X; Liang W; Jiao Y; Hu J; Xu J; Dong F
    Transl Androl Urol; 2020 Oct; 9(5):2179-2191. PubMed ID: 33209682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
    Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
    Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate Cancer Differentiation and Aggressiveness: Assessment With a Radiomic-Based Model vs. PI-RADS v2.
    Chen T; Li M; Gu Y; Zhang Y; Yang S; Wei C; Wu J; Li X; Zhao W; Shen J
    J Magn Reson Imaging; 2019 Mar; 49(3):875-884. PubMed ID: 30230108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A calculator based on prostate imaging reporting and data system version 2 (PI-RADS V2) is a promising prostate cancer predictor.
    Wang H; Tai S; Zhang L; Zhou J; Liang C
    Sci Rep; 2019 May; 9(1):6870. PubMed ID: 31053749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
    Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
    BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.